Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Cash Flows From Operating Activities:
Net loss	$ (18,471,333)	$ (48,976,896)
Adjustments to reconcile net loss to cash used in operating activities
Change in fair value of warrant liability	(4,315,236)	(9,327,326)
Change in fair value of investment option liability	(3,472,726)
Change in fair value of derivative liability	325,000
Stock-based compensation	2,620,671	12,597,001
Stock issued in lieu of cash for services		33,467
Impairment of intangible assets and goodwill	7,453,662	38,678,918
Non-cash income tax benefit	(1,504,302)	(7,454,805)
Inducement expense		1,125,291
Amortization of right-of-use asset	107,291	24,969
Amortization of intangible assets	168,750	643,333
Depreciation expense	159,160	13,310
Change in operating assets and liabilities:
Prepaid expenses and other current assets	(374,058)	826,837
Accounts payable and accrued liabilities	263,686	383,199
Right-of-use operating lease liability	(107,288)	(24,969)
Net cash used in operating activities	(17,146,723)	(11,457,671)
Cash Flows From Investing Activities:
Purchases of property and equipment	(584,165)	(189,719)
Purchase of Diverse Bio license agreement		(675,000)
Cash accretive acquisition of MagicMed		3,055,328
Net cash (used in) provided by investing activities	(584,165)	2,190,609
Cash Flows From Financing Activities:
Proceeds from sale of common stock, warrants, and investment options, net of offering costs	17,222,099	21,614,488
Proceeds from the sale of redeemable non-controlling interest, net of offering costs (see Note 8)	958,038
Proceeds from warrant exercises, net of fees		3,285,171
Net cash provided by financing activities	18,180,137	24,899,659
Effect of foreign exchange rate on cash	(81,364)	144,942
Net increase in cash	367,885	15,777,539
Cash at beginning of year	17,355,999	1,578,460
Cash at end of year	17,723,884	17,355,999
Supplemental disclosure of cash and non-cash transactions:
Cash paid for interest	5,249	10,316
Income taxes paid
Investment options issued in conjunction with common stock issuance	4,323,734
Modification of warrants as part of share capital raise	251,357
Warrants issued in conjunction with common stock issuance	3,595,420
Issuance of embedded derivative	402,000
Preferred dividends attributable to redeemable non-controlling interest	33,014
Accretion of embedded derivative to redemption value	295,976
Issuance of Common Stock pursuant to MagicMed amalgamation		39,042,282
Deferred tax liability incurred due to MagicMed amalgamation		9,061,927
Conversion of preferred stock to common stock		32,754
Fair value of warrants issued		9,981,000
Right-of-use assets obtained in exchange for lease liabilities		$ 201,653